TRIUMPH-1: retatrutide 12 mg, −28.3% at 80 weeks. Efficacy estimand. Treatment-regimen: −25.0%. Tirzepatide (SURMOUNT-1): −20.9% at 72 weeks. No HbA1c screen cap at baseline. 🇺🇸 $LLY www.midgardfinance.com/blog/2026/05... #GLP1 #Retatrutide

1 likes 0 replies